Mimedx Group, Inc. (MDXG)

$5.73

-0.09

(-1.55%)▲

Live

Performance

  • $5.72
    $5.84
    $5.73
    downward going graph

    0.26%

    Downside

    Day's Volatility :2.14%

    Upside

    1.88%

    downward going graph
  • $5.47
    $9.27
    $5.73
    downward going graph

    4.54%

    Downside

    52 Weeks Volatility :40.99%

    Upside

    38.19%

    downward going graph

Returns

PeriodMimedx Group, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-21.35%
3.6%
0.0%
6 Months
-8.49%
10.2%
0.0%
1 Year
-2.84%
19.6%
0.0%
3 Years
-18.37%
16.8%
-23.0%

Highlights

Market Capitalization
858.8M
Book Value
$1.15
Earnings Per Share (EPS)
0.57
PE Ratio
10.26
PEG Ratio
2.97
Wall Street Target Price
12.2
Profit Margin
26.11%
Operating Margin TTM
26.89%
Return On Assets TTM
19.47%
Return On Equity TTM
70.05%
Revenue TTM
340.5M
Revenue Per Share TTM
2.57
Quarterly Revenue Growth YOY
7.3%
Gross Profit TTM
219.5M
EBITDA
66.9M
Diluted Eps TTM
0.57
Quarterly Earnings Growth YOY
13.64
EPS Estimate Current Year
0.27
EPS Estimate Next Year
0.31
EPS Estimate Current Quarter
0.08
EPS Estimate Next Quarter
0.08

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Mimedx Group, Inc.(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 112.91%

Current $5.73
Target $12.20

Company Financials

FY18Y/Y Change
Revenue
359.1M
↑ 11.82%
Net Income
-30.0M
↓ 146.32%
Net Profit Margin
-8.35%
↓ 28.51%
FY19Y/Y Change
Revenue
359.1M
↑ 0.0%
Net Income
-30.0M
↑ 0.0%
Net Profit Margin
-8.35%
↑ 0.0%
FY20Y/Y Change
Revenue
248.2M
↓ 30.88%
Net Income
-49.3M
↑ 64.4%
Net Profit Margin
-19.85%
↓ 11.5%
FY21Y/Y Change
Revenue
258.6M
↑ 4.18%
Net Income
-10.3M
↓ 79.13%
Net Profit Margin
-3.98%
↑ 15.87%
FY22Y/Y Change
Revenue
267.8M
↑ 3.57%
Net Income
-30.2M
↑ 193.6%
Net Profit Margin
-11.27%
↓ 7.29%
FY23Y/Y Change
Revenue
321.5M
↑ 20.03%
Net Income
67.4M
↓ 323.33%
Net Profit Margin
20.98%
↑ 32.25%
Q1 FY23Q/Q Change
Revenue
71.7M
↓ 3.63%
Net Income
-5.0M
↑ 1100.72%
Net Profit Margin
-6.95%
↓ 6.39%
Q2 FY23Q/Q Change
Revenue
81.3M
↑ 13.37%
Net Income
1.2M
↓ 124.08%
Net Profit Margin
1.48%
↑ 8.43%
Q3 FY23Q/Q Change
Revenue
81.7M
↑ 0.56%
Net Income
6.8M
↑ 463.42%
Net Profit Margin
8.27%
↑ 6.79%
Q4 FY23Q/Q Change
Revenue
86.8M
↑ 6.27%
Net Income
62.7M
↑ 827.2%
Net Profit Margin
72.19%
↑ 63.92%
Q1 FY24Q/Q Change
Revenue
84.7M
↓ 2.44%
Net Income
9.3M
↓ 85.23%
Net Profit Margin
10.93%
↓ 61.26%
Q2 FY24Q/Q Change
Revenue
87.2M
↑ 2.95%
Net Income
17.6M
↑ 90.31%
Net Profit Margin
20.21%
↑ 9.28%
FY18Y/Y Change
Total Assets
122.8M
↑ 1.31%
Total Liabilities
73.2M
↑ 54.22%
FY19Y/Y Change
Total Assets
122.8M
↑ 0.0%
Total Liabilities
73.2M
↑ 0.0%
FY20Y/Y Change
Total Assets
202.0M
↑ 64.46%
Total Liabilities
202.2M
↑ 176.25%
FY21Y/Y Change
Total Assets
187.9M
↓ 6.98%
Total Liabilities
187.8M
↓ 7.09%
FY22Y/Y Change
Total Assets
171.4M
↓ 8.78%
Total Liabilities
189.4M
↑ 0.84%
FY23Y/Y Change
Total Assets
239.0M
↑ 39.44%
Total Liabilities
96.3M
↓ 49.14%
Q1 FY23Q/Q Change
Total Assets
168.2M
↓ 1.91%
Total Liabilities
186.1M
↓ 1.75%
Q2 FY23Q/Q Change
Total Assets
176.4M
↑ 4.89%
Total Liabilities
189.0M
↑ 1.58%
Q3 FY23Q/Q Change
Total Assets
189.0M
↑ 7.17%
Total Liabilities
187.7M
↓ 0.72%
Q4 FY23Q/Q Change
Total Assets
239.0M
↑ 26.47%
Total Liabilities
96.3M
↓ 48.68%
Q1 FY24Q/Q Change
Total Assets
221.7M
↓ 7.26%
Total Liabilities
66.0M
↓ 31.54%
Q2 FY24Q/Q Change
Total Assets
230.2M
↑ 3.84%
Total Liabilities
62.1M
↓ 5.77%
FY18Y/Y Change
Operating Cash Flow
35.8M
↓ 43.13%
Investing Cash Flow
-9.2M
↑ 70.84%
Financing Cash Flow
-8.9M
↓ 85.21%
FY19Y/Y Change
Operating Cash Flow
35.8M
↑ 0.0%
Investing Cash Flow
504.0K
↓ 105.47%
Financing Cash Flow
-8.9M
↑ 0.0%
FY20Y/Y Change
Operating Cash Flow
-39.4M
↓ 210.1%
Investing Cash Flow
-4.6M
↓ 1003.77%
Financing Cash Flow
62.9M
↓ 803.59%
FY21Y/Y Change
Operating Cash Flow
-2.0M
↓ 94.97%
Investing Cash Flow
-3.4M
↓ 25.47%
Financing Cash Flow
-3.4M
↓ 105.33%
FY22Y/Y Change
Operating Cash Flow
-17.9M
↑ 802.77%
Investing Cash Flow
-2.7M
↓ 21.65%
Financing Cash Flow
-580.0K
↓ 82.7%
Q1 FY23Q/Q Change
Operating Cash Flow
-4.0M
↓ 28.02%
Investing Cash Flow
-677.0K
↓ 60.39%
Financing Cash Flow
-4.0K
↓ 106.06%
Q2 FY23Q/Q Change
Operating Cash Flow
7.8M
↓ 292.07%
Investing Cash Flow
-348.0K
↓ 48.6%
Financing Cash Flow
4.0K
↓ 200.0%

Technicals Summary

Sell

Neutral

Buy

Mimedx Group, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Mimedx Group, Inc.
Mimedx Group, Inc.
-5.06%
-8.49%
-2.84%
-18.37%
-19.5%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Mimedx Group, Inc.
Mimedx Group, Inc.
10.26
10.26
2.97
0.27
0.7
0.19
NA
1.15
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Mimedx Group, Inc.
Mimedx Group, Inc.
Buy
$858.8M
-19.5%
10.26
26.11%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Mimedx Group, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 84.70M → 87.20M (in $), with an average increase of 2.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 9.26M → 17.62M (in $), with an average increase of 47.5% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 87.2%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 63.2%

Institutional Holdings

  • Essex Woodlands Health Ventures

    19.21%

  • BlackRock Inc

    6.34%

  • Vanguard Group Inc

    4.72%

  • Trigran Investments Inc

    3.05%

  • Paradigm Capital Management, Inc.

    2.84%

  • State Street Corp

    2.70%

Company Information

mimedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. the company processes the human placental tissue utilizing its proprietary purion® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. mimedx has supplied more than two million allografts, through both direct and consignment shipments. for additional information, please visit www.mimedx.com.

Organization
Mimedx Group, Inc.
Employees
895
CEO
Mr. Joseph H. Capper
Industry
Biotechnology

Discover More

FAQs